Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ratner

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Gynecologic Oncology|October 22, 2011
A survey of gynecologic oncologists regarding the end-of-life discussion: a pilot studyKarim S El-Sahwi, Jessica Illuzzi, Joyce Varughese, et al.
Biochemical Pharmacology|August 19, 2014
Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexesKimiko Ishiguro, Z Ping Lin, Philip G Penketh, et al.
Gynecologic Oncology|January 12, 2020
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)Alessandro D Santin, Wei Deng, Michael Frumovitz, et al.
Gynecologic Oncology|May 7, 2016
Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data BaseNataniel H Lester-Coll, Henry S Park, Charles E Rutter, et al.
British Journal of Cancer|March 11, 2016
Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repairElena S Ratner, Yong-Lian Zhu, Philip G Penketh, et al.
Scientific Reports|April 14, 2021
In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancerZ Ping Lin, Nour N Al Zouabi, Mark L Xu, et al.
Gynecologic Oncology Reports|September 5, 2020
Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532]Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.
The American Journal of Emergency Medicine|March 31, 2015
Comparison of airway intubation devices when using a biohazard suit: a feasibility studyKevin R Weaver, Gavin C Barr, Kayla R Long, et al.
Journal of Palliative Medicine|November 26, 2024
Top Ten Tips Palliative Care Clinicians Should Know About Addressing Patient Sexuality and Intimacy in Serious IllnessDanielle Chammas, Alan W Shindel, Tami Serene Rowen, et al.
Journal of Gynecologic Oncology|August 25, 2021
Financial toxicity in patients with gynecologic malignancies: a cross sectional studyBurak Zeybek, Emily Webster, Natalia Pogosian, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Gynecologic Oncology|October 22, 2011
A survey of gynecologic oncologists regarding the end-of-life discussion: a pilot studyKarim S El-Sahwi, Jessica Illuzzi, Joyce Varughese, et al.
Biochemical Pharmacology|August 19, 2014
Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexesKimiko Ishiguro, Z Ping Lin, Philip G Penketh, et al.
Gynecologic Oncology|January 12, 2020
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)Alessandro D Santin, Wei Deng, Michael Frumovitz, et al.
Gynecologic Oncology|May 7, 2016
Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data BaseNataniel H Lester-Coll, Henry S Park, Charles E Rutter, et al.
British Journal of Cancer|March 11, 2016
Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repairElena S Ratner, Yong-Lian Zhu, Philip G Penketh, et al.
Scientific Reports|April 14, 2021
In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancerZ Ping Lin, Nour N Al Zouabi, Mark L Xu, et al.
Gynecologic Oncology Reports|September 5, 2020
Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532]Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.
The American Journal of Emergency Medicine|March 31, 2015
Comparison of airway intubation devices when using a biohazard suit: a feasibility studyKevin R Weaver, Gavin C Barr, Kayla R Long, et al.
Journal of Palliative Medicine|November 26, 2024
Top Ten Tips Palliative Care Clinicians Should Know About Addressing Patient Sexuality and Intimacy in Serious IllnessDanielle Chammas, Alan W Shindel, Tami Serene Rowen, et al.
Journal of Gynecologic Oncology|August 25, 2021
Financial toxicity in patients with gynecologic malignancies: a cross sectional studyBurak Zeybek, Emily Webster, Natalia Pogosian, et al.
Pageof 11